Pss34 - Cost-Effectiveness of Intravitreal Aflibercept Versus Ranibizumab in the Treatment of Diabetic Macular Edema in Spain

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2534
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pss25 - Cost-Effectiveness Analysis of Intravitreal Aflibercept Versus Ranibizumab in the Treatment of Diabetic Macular Edema (Dme) Under the Brazilian Public Healthcare System (Sus)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Ranibizumab Versus Aflibercept in the Treatment of Visual Impairment Due to Diabetic Macular Edema: A UK Healthcare Perspective

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2015English

Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment

Ophthalmology
Ophthalmology
2012English

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

Ophthalmology
Ophthalmology
2016English

Effect of Intravitreal Aflibercept on Recalcitrant Diabetic Macular Edema

International Journal of Retina and Vitreous
Ophthalmology
2017English

Intravitreal Ranibizumab for Diabetic Macular Edema With Prompt Versus Deferred Laser Treatment: 5-Year Randomized Trial Results

Ophthalmology
Ophthalmology
2015English

Association of Changes in Macular Perfusion With Ranibizumab Treatment for Diabetic Macular Edema

JAMA Ophthalmology
Ophthalmology
2018English

Intravitreal Corticosteroids in the Management of Diabetic Macular Edema

Current Ophthalmology Reports
Ophthalmology
2013English

Systematic Review and Mixed Treatment Comparison of Intravitreal Aflibercept With Other Therapies for Diabetic Macular Edema (DME)

BMC Ophthalmology
MedicineOphthalmology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy